The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ESMO 2019 | ClarIDHy: updates and initial findings for ivosidenib in CCA

Name: ClarIDHy: updates and initial findings for ivosidenib in CCA
Uploaded: 2019-09-28T00:00:00Z
Duration: 2 min 29 s
Description: Ghassan Abou-Alfa, MD, Memorial Sloan Kettering Cancer Center, New York, NY, runs through the aims and initial findings of the ClarIDHy study (NCT02989857); a Phase III study of ivosidenib vs placebo in patients with advanced cholangiocarcinoma (CCA) with an IDH1 mutation. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Ghassan Abou-Alfa • 28 Sep 2019

ESMO 2019

Bile Duct Cancer Gastrointestinal Cancer Ivosidenib

ClarIDHy

Ghassan Abou-Alfa, MD, Memorial Sloan Kettering Cancer Center, New York, NY, runs through the aims and initial findings of the ClarIDHy study (NCT02989857); a Phase III study of ivosidenib vs placebo in patients with advanced cholangiocarcinoma (CCA) with an IDH1 mutation. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.